DGIdb - PERTUZUMAB Drug Record

PERTUZUMAB chembl:CHEMBL2007641 ApprovedAntineoplastic

Alternate Names:

PERTUZUMAB
PERJETA
OMNITARG
OMNITARG PERJETA
RHUMAB-2C4
RG-1273
MOAB 2C4
MONOCLONAL ANTIBODY 2C4
2C4 ANTIBODY
chemidplus:380610-27-5
drugbank:06366
chembl:CHEMBL2007641
rxcui:1298944

Drug Info:

FDA Approval	not approved
Drug Class	monoclonal antibody
Drug Indications	antineoplastic agent
FDA Approval	Breast cancer (HER2+)
Drug Class	Therapeutic Antibodies

(9 More Sources)

Publications:

Franklin et al., 2004, Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex., Cancer Cell
Yarlagadda B et al., 2019, Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma., NPJ Precis Oncol
Meric-Bernstam F et al., 2019, Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study., Lancet Oncol
Hainsworth JD et al., 2018, Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study., J Clin Oncol
Baselga et al., 2012, Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer., N. Engl. J. Med.
Swain et al., 2015, Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer., N. Engl. J. Med.
Blumenthal et al., 2013, First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer., Clin. Cancer Res.
Martin et al., 2016, Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study., Ann. Oncol.
Kodack et al., 2017, The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation., Sci Transl Med
Bertotti et al., 2011, A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer., Cancer Discov
Hanker et al., 2013, Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies., Proc. Natl. Acad. Sci. U.S.A.
Jaiswal et al., 2013, Oncogenic ERBB3 mutations in human cancers., Cancer Cell
Thomas et al., 2014, HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models., Oncotarget
Capparelli et al., 2015, ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas., Cancer Res.
Heining C et al., 2018, <i>NRG1</i> Fusions in <i>KRAS</i> Wild-Type Pancreatic Cancer., Cancer Discov

PERTUZUMAB ERBB3

Interaction Score: 1.29

Interaction Types & Directionality:

n/a

Interaction Info:

Variant Effect gain-of-function

Pathway activation

Clinical Status preclinical

PMIDs:
23680147 25216528 26206558

Sources:
DoCM CIViC
PERTUZUMAB ERBB2

Interaction Score: 1.16

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Notes Prevents dimerization of HER2 with other HER receptors

combination therapy Trastuzumab + Pertuzumab

Indication/Tumor Type Her2-receptor positive breast cancer

PMIDs:
15093539 31453370 30857956 29320312 22149875 25693012 23801166 27052654 28539475 22586653 23940356

Sources:
TALC ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions CIViC PharmGKB TTD FDA OncoKB
PERTUZUMAB NRG1

Interaction Score: 0.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29802158

Sources:
CIViC
PERTUZUMAB PGR

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
PERTUZUMAB BRAF

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29320312

Sources:
CIViC
PERTUZUMAB ESR2

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PERTUZUMAB PIK3CA

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BKM120 + Trastuzumab + Pertuzumab

Indication/Tumor Type Her2-receptor positive breast cancer

Response Type sensitive

PMIDs:
23940356

Sources:
JAX-CKB
PERTUZUMAB ESR1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA

MyCancerGenome: PERTUZUMAB
- Version: 20-Jun-2017
Alternate Names:

MOAB2C4 Development Name

PERTUZUMAB Generic Name

PERJETA Trade Name

Drug Info:

Drug Class Therapeutic Antibodies

FDA Approval Breast cancer (HER2+)

Publications:
TdgClinicalTrial: PERTUZUMAB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class monoclonal antibody

FDA Approval not approved

Publications:
DoCM: PERTUZUMAB
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Jaiswal et al., 2013, Oncogenic ERBB3 mutations in human cancers., Cancer Cell

JAX-CKB: Pertuzumab

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Bertotti et al., 2011, A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer., Cancer Discov

Blumenthal et al., 2013, First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer., Clin. Cancer Res.

Hanker et al., 2013, Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies., Proc. Natl. Acad. Sci. U.S.A.

CIViC: PERTUZUMAB

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Hainsworth JD et al., 2018, Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study., J Clin Oncol

Yarlagadda B et al., 2019, Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma., NPJ Precis Oncol

Baselga et al., 2012, Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer., N. Engl. J. Med.

TALC: PERTUZUMAB
- Version: 12-May-2016
Alternate Names:

PERTUZUMAB Primary Drug Name

PERTUZUMAB Drug Generic Name

PERJETA Drug Trade Name

Drug Info:

Publications:
TTD: Pertuzumab
- Version: 2020.06.01
Alternate Names:

D0CI4E TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL2007641
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
OncoKB: Pertuzumab
- Version: 23-July-2020
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: PERTUZUMAB
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL2007641
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
FDA: Pertuzumab
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:
PharmGKB: pertuzumab
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Variant Effect	gain-of-function
Pathway	activation
Clinical Status	preclinical

Notes	Prevents dimerization of HER2 with other HER receptors
combination therapy	Trastuzumab + Pertuzumab
Indication/Tumor Type	Her2-receptor positive breast cancer

combination therapy	BKM120 + Trastuzumab + Pertuzumab
Indication/Tumor Type	Her2-receptor positive breast cancer
Response Type	sensitive

MOAB2C4	Development Name
PERTUZUMAB	Generic Name
PERJETA	Trade Name

PERTUZUMAB	Primary Drug Name
PERTUZUMAB	Drug Generic Name
PERJETA	Drug Trade Name

antibody (inhibitory)
inhibitor (inhibitory)

PERTUZUMAB Drug Record

PERTUZUMAB chembl:CHEMBL2007641 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Variant Effect gain-of-function Pathway activation Clinical Status preclinical

PMIDs: 23680147 25216528 26206558

Sources: DoCM CIViC

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Notes Prevents dimerization of HER2 with other HER receptors combination therapy Trastuzumab + Pertuzumab Indication/Tumor Type Her2-receptor positive breast cancer

PMIDs: 15093539 31453370 30857956 29320312 22149875 25693012 23801166 27052654 28539475 22586653 23940356

Sources: TALC ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions CIViC PharmGKB TTD FDA OncoKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29802158

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29320312

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy BKM120 + Trastuzumab + Pertuzumab Indication/Tumor Type Her2-receptor positive breast cancer Response Type sensitive

PMIDs: 23940356

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

MyCancerGenome: PERTUZUMAB

Alternate Names: MOAB2C4 Development Name PERTUZUMAB Generic Name PERJETA Trade Name

Drug Info: Drug Class Therapeutic Antibodies FDA Approval Breast cancer (HER2+)

Publications:

TdgClinicalTrial: PERTUZUMAB

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class monoclonal antibody FDA Approval not approved

Publications:

DoCM: PERTUZUMAB

Alternate Names:

Drug Info:

Publications: Jaiswal et al., 2013, Oncogenic ERBB3 mutations in human cancers., Cancer Cell

JAX-CKB: Pertuzumab

Alternate Names:

Drug Info:

CIViC: PERTUZUMAB

Alternate Names:

Drug Info:

TALC: PERTUZUMAB

Alternate Names: PERTUZUMAB Primary Drug Name PERTUZUMAB Drug Generic Name PERJETA Drug Trade Name

Drug Info:

Publications:

TTD: Pertuzumab

Alternate Names: D0CI4E TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL2007641

Alternate Names:

Drug Info:

Publications:

OncoKB: Pertuzumab

Alternate Names:

Drug Info:

Publications:

ClearityFoundationBiomarkers: PERTUZUMAB

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL2007641

Alternate Names:

Drug Info:

Publications:

FDA: Pertuzumab

Interaction Types & Directionality:

n/a

Interaction Info:

Variant Effect gain-of-function

Pathway activation

Clinical Status preclinical

PMIDs:
23680147 25216528 26206558

Sources:
DoCM CIViC

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Notes Prevents dimerization of HER2 with other HER receptors

combination therapy Trastuzumab + Pertuzumab

Indication/Tumor Type Her2-receptor positive breast cancer

PMIDs:
15093539 31453370 30857956 29320312 22149875 25693012 23801166 27052654 28539475 22586653 23940356

Sources:
TALC ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions CIViC PharmGKB TTD FDA OncoKB

Interaction Types & Directionality:

n/a

PMIDs:
29802158

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
29320312

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BKM120 + Trastuzumab + Pertuzumab

Indication/Tumor Type Her2-receptor positive breast cancer

Response Type sensitive

PMIDs:
23940356

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Alternate Names:

MOAB2C4 Development Name

PERTUZUMAB Generic Name

PERJETA Trade Name

Drug Info:

Drug Class Therapeutic Antibodies

FDA Approval Breast cancer (HER2+)

Drug Info:

Drug Indications antineoplastic agent

Drug Class monoclonal antibody

FDA Approval not approved

Publications:

Jaiswal et al., 2013, Oncogenic ERBB3 mutations in human cancers., Cancer Cell

Alternate Names:

PERTUZUMAB Primary Drug Name

PERTUZUMAB Drug Generic Name

PERJETA Drug Trade Name

Alternate Names:

D0CI4E TTD Drug ID